Research from the University of Warwick indicates that most people are in favor of newborn screening for the potentially deadly condition spinal muscular atrophy (SMA). The study Newborn genetic ...

People with spinal muscle atrophy (SMA), an inherited neuromuscular disease, usually experience muscle weakness that impacts movement. New research suggests that electrical spinal cord stimulation ...

Basel, July 2, 2026 – Novartis today announced that the European Commission (EC) has approved Itvisma ® (onasemnogene ...

Spinal muscular atrophy type 3 is a rare and less severe form of the condition. Symptoms usually start in childhood or adolescence, and life expectancy is typically unaffected. Treatment may help slow ...

Spinal muscular atrophy (SMA) is a genetic neuromuscular disease affecting specialized nerve cells that control voluntary muscle movement, according to the Muscular Dystrophy Association (MDA). It can ...

As treatment for spinal muscular atrophy (SMA) has drastically improved over the last decade, so too have survival rates and the number of people with SMA living well into adulthood. In line with that ...

The approval is supported by data from the STEER, Phase IIIb STRENGTH and Phase I/II STRONG studies.

RALEIGH, N.C., June 24, 2026 /PRNewswire/ -- Becoming rentABLE, a platform that connects travelers with disabilities to trusted accessible short-term rentals (STRs), today announced a new ...

SMA type 3 is a hereditary disease that affects motor neurons. People may also refer to it as Kugelberg-Welander disease. Symptoms usually begin after 18 months of age. Children with SMA type 3 can ...

SMA type 2, previously known as Dubowitz disease, is a hereditary disease that affects motor neurons. It typically becomes noticeable around the ages of 6 to 18 months, when children with the ...

Spinal muscular atrophy (SMA) type 4 is the rarest and mildest form of the condition. Symptoms don’t start until adulthood and progress slowly, but experts still recommend early treatment. It doesn’t ...